XFOR
$4.23
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
Recent News
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +38.89% and +53.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
X4 Pharmaceuticals: Q4 Earnings Snapshot
BOSTON (AP) — X4 Pharmaceuticals, Inc. XFOR) on Tuesday reported a loss of $23.9 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of 22 cents.
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) delivered earnings and revenue surprises of -12.50% and -36.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts. All three names carry verified Buy or Overweight ratings, and the gap between current trading prices and analyst targets ranges from substantial to dramatic. Three Calls, Three Catalysts ... X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Vericel Corporation (VCEL) Matches Q4 Earnings Estimates
Vericel (VCEL) delivered earnings and revenue surprises of +0.74% and +1.83%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?